Amneal Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
UPDATE: Amneal Pharmaceuticals (AMRX) Tops Q1 EPS by 2c, Revenues Miss; Offers FY21 Revenues Outlook
May 7, 2021 6:09 AM EDT(Updated - May 7, 2021 6:10 AM EDT)
Amneal Pharmaceuticals (: AMRX) reported Q1 EPS of $0.20, $0.02 better than the analyst estimate of $0.18. Revenue for the quarter came in at $493 million versus the consensus estimate of $513.24 million.
Amneal delivered solid first quarter results, continuing our positive momentum as... More
